Iktos utilizes generative AI and automated synthesis to streamline drug discovery, significantly reducing the time to identify viable drug candidates to under two years. By integrating AI-driven design, retrosynthesis, and robotics, the platform addresses the inefficiencies in traditional drug development processes, enhancing the speed and success rate of new treatment development.
Funding
$21M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery processes are inefficient and time-consuming, often taking many years to identify viable drug candidates. These inefficiencies stem from the iterative nature of design, synthesis, testing, and analysis (DMTA) cycles, which require significant manual effort and resources.
Solution
Iktos offers an AI-driven drug discovery platform that streamlines the DMTA cycle, significantly reducing the time and cost associated with identifying promising drug candidates. The platform integrates generative AI for molecular design (Makya), AI-driven retrosynthesis (Spaya), and automated synthesis through robotics, creating a closed-loop system for rapid iteration and optimization. By combining these technologies, Iktos accelerates the development of new treatments, enabling researchers to explore a wider chemical space and identify compounds with improved properties. The platform facilitates a more efficient and data-driven approach to drug discovery, ultimately leading to faster development timelines and increased success rates.
Target Audience
Iktos primarily targets pharmaceutical and biotech companies, as well as academic institutions, seeking to accelerate their drug discovery programs and improve the efficiency of their research and development efforts.
Features
- **Makya:** Generative AI SaaS platform for de novo drug design, focusing on synthetic accessibility and multi-parametric optimization, including 3D constraints.
- **Spaya:** AI-driven retrosynthesis platform that identifies feasible synthetic routes from target compounds to commercially available starting materials.
- **Iktos Robotics:** Autonomous lab for automated compound synthesis and analysis, with ongoing integration of purification and biological testing.
- High-throughput data generation and iterative optimization through a closed-loop DMTA process.
- Customizable synthesis steps and constraints within the retrosynthesis platform.
- Integration with various data providers to enhance the retrosynthesis process.